Back to results
US 2025/0051802 A1Published application
Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
AssigneeBayer Aktiengesellschaft
InventorsAndre COHNEN, Florian RICHTER, Andreas NEERINCX
Life of this patent
Estimating the term…
Abstract
Described herein are novel systems for targeting, editing or manipulating DNA in a cell, using novel M-SmallCas9 nucleases and variants thereof. The M-SmallCas9 nucleases are derived from wildtype or parental small type II CRISPR Cas9 endonucleases, and display improved fidelity compared to parental type II CRISPR Cas9 enzymes in combination with a simple PAM sequences and are small endonuclease size.
Claims10
1:
- A polypeptide selected from the group consisting of:
- (I) SEQ ID NO:
- 1, or any polypeptide sequence that is at least 95% identical to SEQ ID NO:
- 1 and comprises the following amino acid substitutions compared to the Cas9 sequence from Staphylococcus aureus (NCBI RefSeq ID J7RUA5.1):
- 11017K, P1013E, R991M;
- (II) SEQ ID NO:
- 2, or any polypeptide sequence that is at least 95% identical to SEQ ID NO:
- 2 and comprises the following amino acid substitutions compared to the Cas9 sequence from Staphylococcus aureus (NCBI RefSeq ID J7RUA5.1):
- 11017K, P1013E, R991M, L989R;
- (III) SEQ ID NO:
- 3, or any polypeptide sequence that is at least 95% identical to SEQ ID NO:
- 3 and comprises the following amino acid substitutions compared to the Cas9 sequence from Staphylococcus aureus (NCBI RefSeq ID J7RUA5.1):
- 11017K, P1013E, R991M. L989R, R1012G, D1010I, L1005C;
- (IV) SEQ ID NO:
- 4, or any polypeptide sequence that is at least 95% identical to SEQ ID NO:
- 4 and comprises the following amino acid substitutions compared to the Cas9 sequence from Staphylococcus aureus (NCBI RefSeq ID J7RUA5.1):
- 11017K, P1013E, R991M. L989R, N986S, L988T;
- and
- (V)_SEQ ID NO:
- 5, or any polypeptide sequence that is at least 95% identical to SEQ ID NO:
- 5 and comprises the following amino acid substitutions compared to the Cas9 sequence from Staphylococcus aureus (NCBI RefSeq ID J7RUA5.1):
- 11017K, P1013E, R991M. L989R, R1012G, D1010I, L1005C, N986S, L988T;
- and wherein the amino acid in front of the position in the Staphylococcus aureus Cas9 sequence is the amino acid that is present in the polypeptide.
20 more elements
2:
- The polypeptide of claim 1, wherein the polypeptide is selected from the group consisting of:
- SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, and SEQ ID NO:
- 5.
4 more elements
3:
- The polypeptide of claim 1, wherein the polypeptide is selected from the group consisting of:
- SEQ ID NO:
- 3, SEQ ID NO:
- 4, and SEQ ID NO:
- 5.
2 more elements
4:
- The polypeptide of claim 1, wherein the polypeptide is SEQ ID NO:
- 5.
5:
- A composition comprising:
- (I) the polypeptide of claim 1;
- and
- (II) one or more single heterologous guide RNA(s) (sgRNA) or DNA(s) that allow the generation of such one or more sgRNA(s) in situ, each sgRNA or DNA encoding an sgRNA comprising:
- (a) an engineered DNA targeting segment that can hybridize to a target sequence in a polynucleotide locus,
- (b) a tracr mate sequence, and
- (c) a tracr RNA sequence,
- wherein the tracr mate sequence can hybridize to the tracr sequence, and wherein (a), (b), and (c) are arranged in a 5′ to 3′ orientation.
5 more elements
6:
- The composition of claim 5, wherein the engineered DNA targeting segment is directly adjacent to a PAM sequence on its 3′ end or a PAM sequence is part of the DNA targeting sequence in its 3′ portion.
7:
- A method of targeting, editing, modifying, or manipulating a target DNA at one or more locations in a cell or in vitro, the method comprising;
- (I) introducing the polypeptide of claim 1 or a nucleic acid encoding such polypeptide into the cell or into the in vitro environment, wherein the polypeptide is heterologous;
- and
- (II) introducing one or more single heterologous guide RNA(s) (sgRNA) or DNA(s) encoding such one or more sgRNA(s) into the cell or the in vitro environment, each sgRNA or DNA encoding the sgRNA comprising:
- (a) an engineered DNA targeting segment comprising an RNA and capable of hybridizing to a target sequence in a polynucleotide locus,
- (b) a tracr mate sequence comprised of RNA, and
- (c) a tracr RNA sequence comprised of RNA,
- wherein the tracr mate sequence hybridizes to the tracr sequence, and wherein (a), (b), and (c) are arranged in a 5′ to 3′ orientation;
- and
- (III) creating one or more nicks or cuts or base edits in the target DNA, wherein the polypeptide is directed to the target DNA by the sgRNA in its processed or unprocessed form.
7 more elements
(canceled)
9:
- A cell comprising:
- (I) the polypeptide of claim 1, or a nucleic acid encoding such polypeptide;
- and
- (II) one or more single heterologous guide RNA(s) (sgRNA) or DNA(s) suitable for the generation of such one or more sgRNA in situ, each sgRNA comprising:
- (a) an engineered DNA targeting segment that can hybridize to a target sequence in a polynucleotide locus,
- (b) a tracr mate sequence, and
- (c) a tracr RNA sequence,
- wherein the tracr mate sequence can hybridize to the tracr sequence, and wherein (a), (b), and (c) are arranged in a 5′ to 3′ orientation.
5 more elements
10:
- A kit comprising:
- (I) a nucleic acid sequence encoding the polypeptide of claim 1, wherein the nucleic acid sequence encoding the polypeptide is operably linked to a promoter;
- and
- (II) one or more single heterologous guide RNA(s) (sgRNA) or DNA(s) suitable for the generation of such one or more sgRNA in situ, each sgRNA comprising:
- (a) an engineered DNA targeting segment that can hybridize to a target sequence in a polynucleotide locus,
- (b) a tracr mate sequence, and
- (c) a tracr RNA sequence,
- wherein the tracr mate sequence can hybridize to the tracr sequence, and wherein (a), (b), and (c) are arranged in a 5′ to 3′ orientation.
5 more elements
Dependencies are inferred from the claim text.